DUBLIN (dpa-AFX) - Cosmo Pharmaceuticals N.V. (COPN.SW) announced the renewal of its multi-year manufacturing and supply agreement with Takeda.
As per the deal, Cosmo will continue producing Mesalazine MMX 1200 mg-marketed as Lialda in the USA and Mezavant in Europe-a once-daily oral treatment for ulcerative colitis.
Cosmo's advanced manufacturing site in Lainate (Italy) is approved by multiple regulatory authorities worldwide.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News